Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H18N4O2S |
Molecular Weight | 366.4386 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cc1c(CS(=O)c2nc3ccc(cc3[nH]2)-n4cccc4)nccc1OC
InChI
InChIKey=HRRXCXABAPSOCP-UHFFFAOYSA-N
InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)
Molecular Formula | C19H18N4O2S |
Molecular Weight | 366.4386 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Ilaprazole or IY-81149 (2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl -5-(1H-pyrrol-1-yl)-1H-benzimidazole, CAS 172152-36-2) is a proton pump inhibitor. Ilaprazole revealed the characteristics as a strong proton pump inhibitor, and its potency against gastric acid secretion was superior to that of the reference drug, omeprazole. Ilaprazole is approved in China and South Korea for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Recently it was discovered that ilaprazole inhibited the cancer growth by targeting T-cell-originated protein kinase (TOPK) both in vitro and in vivo.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11304936 |
6.0 µM [IC50] | ||
Target ID: CHEMBL4896 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28388576 |
111.0 µM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Noltec Approved UseIlaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Launch Date1.19111038E12 |
|||
Primary | Noltec Approved UseIlaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Launch Date1.19111038E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of IY81149 with omeprazole in rat reflux oesophagitis. | 2000 Oct-Dec |
|
The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study. | 2014 Sep |
|
Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase. | 2017 Jun 13 |
Patents
Sample Use Guides
Short-term treatment of duodenal ulcer: Normally, 10 mg of adult is administered orally once a day. It is usually administered for up to 4 weeks.
Short-term treatment of gastric ulcer: Normally, an adult dose of 10 mg is orally administered once a day. It is usually administered for 4 to 6 weeks.
This medicine should be swallowed with water 1 hour before meals and should not be chewed or crushed.
The recommended adult dosage of Ilaprazole is 5-20 mg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28388576
Ilaprazole exhibited potent inhibitory activities against the growth of HCT116 cells (IC50 = 40 uM) and ES-2 cells (IC50 = 33.2 uM). Ilaprazole (100 and 50 uM) induces apoptosis in ES-2 and HCT116 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 11:40:35 UTC 2021
by
admin
on
Sat Jun 26 11:40:35 UTC 2021
|
Record UNII |
776Q6XX45J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29723
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
172152-36-2
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
8158
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
776Q6XX45J
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
3961
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
C119615
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
Ilaprazole
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
DB11964
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
CHEMBL2106370
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
SUB130420
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
214351
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY | |||
|
C65887
Created by
admin on Sat Jun 26 11:40:35 UTC 2021 , Edited by admin on Sat Jun 26 11:40:35 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |